MedDataX Logo

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

NCT ID: NCT00615290

Last Updated: 2014-08-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To obtain information on clinical practices for patients treated by Aptivus in real life

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

NCT00531206

HIV Infections
COMPLETED

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

NCT00976950

HIV Infections
COMPLETED

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

NCT00530920

HIV Infections
COMPLETED PHASE2

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

NCT00447902

HIV Infections
TERMINATED PHASE3

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

NCT00933205

HIV Infections
APPROVED_FOR_MARKETING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tipranavir

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV positive patients for whom Aptivus treatment is initiated by their physician
* Aptivus SCP respect
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site

Agen, , France

Site Status

Boehringer Ingelheim Investigational Site

Aix-en-Provence, , France

Site Status

Boehringer Ingelheim Investigational Site

Amiens, , France

Site Status

Boehringer Ingelheim Investigational Site

Argenteuil, , France

Site Status

Boehringer Ingelheim Investigational Site

Aulnay-sous-Bois, , France

Site Status

Boehringer Ingelheim Investigational Site

Auxerre, , France

Site Status

Boehringer Ingelheim Investigational Site

Belfort, , France

Site Status

Boehringer Ingelheim Investigational Site

Besançon, , France

Site Status

Boehringer Ingelheim Investigational Site

Béziers, , France

Site Status

Boehringer Ingelheim Investigational Site

Bondy, , France

Site Status

Boehringer Ingelheim Investigational Site

Bordeaux, , France

Site Status

Boehringer Ingelheim Investigational Site

Briis-sous-Forges, , France

Site Status

Boehringer Ingelheim Investigational Site

Cahors, , France

Site Status

Boehringer Ingelheim Investigational Site

Cannes, , France

Site Status

Boehringer Ingelheim Investigational Site

Chartres, , France

Site Status

Boehringer Ingelheim Investigational Site

Corbeil-Essonnes, , France

Site Status

Boehringer Ingelheim Investigational Site

Creil, , France

Site Status

Boehringer Ingelheim Investigational Site

Créteil, , France

Site Status

Boehringer Ingelheim Investigational Site

Dax, , France

Site Status

Boehringer Ingelheim Investigational Site

Digne-les-Bains, , France

Site Status

Boehringer Ingelheim Investigational Site

Garches, , France

Site Status

Boehringer Ingelheim Investigational Site

La Roche-sur-Yon, , France

Site Status

Boehringer Ingelheim Investigational Site

Le Mans, , France

Site Status

Boehringer Ingelheim Investigational Site

Le Petit-Quevilly, , France

Site Status

Boehringer Ingelheim Investigational Site

Libourne, , France

Site Status

Boehringer Ingelheim Investigational Site

Lyon, , France

Site Status

Boehringer Ingelheim Investigational Site

Mantes-la-Jolie, , France

Site Status

Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

Boehringer Ingelheim Investigational Site

Metz, , France

Site Status

Boehringer Ingelheim Investigational Site

Mulhouse, , France

Site Status

Boehringer Ingelheim Investigational Site

Nancy, , France

Site Status

Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

Boehringer Ingelheim Investigational Site

Nevers, , France

Site Status

Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

Boehringer Ingelheim Investigational Site

Orléans, , France

Site Status

Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

Boehringer Ingelheim Investigational Site

Périgueux, , France

Site Status

Boehringer Ingelheim Investigational Site

Poitiers, , France

Site Status

Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

Boehringer Ingelheim Investigational Site

Saint-Brieuc, , France

Site Status

Boehringer Ingelheim Investigational Site

Saint-Mandé, , France

Site Status

Boehringer Ingelheim Investigational Site

Saint-Nazaire, , France

Site Status

1182.127.3301 Boehringer Ingelheim Investigational Site

Strasbourg, , France

Site Status

Boehringer Ingelheim Investigational Site

Strasbourg, , France

Site Status

Boehringer Ingelheim Investigational Site

Suresnes, , France

Site Status

Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

Boehringer Ingelheim Investigational Site

Valenciennes, , France

Site Status

Boehringer Ingelheim Investigational Site

Villeneuve Saint G, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1182.127

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
NCT00034866 COMPLETED PHASE2
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
NCT00146328 COMPLETED PHASE2/PHASE3
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
NCT00352066 COMPLETED PHASE1
Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options
NCT00144287 COMPLETED PHASE3
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
NCT00097799 APPROVED_FOR_MARKETING
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
NCT00144105 TERMINATED PHASE2
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
NCT00275444 COMPLETED PHASE2
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
NCT00440271 TERMINATED PHASE3
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
NCT00056641 COMPLETED PHASE2
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
NCT01602822 TERMINATED PHASE4
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
NCT00389207 COMPLETED PHASE3
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
NCT00054717 COMPLETED PHASE3
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients
NCT02239835 TERMINATED PHASE2
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
NCT00027339 COMPLETED PHASE2
Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression
NCT01471821 COMPLETED PHASE4
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
NCT00135395 COMPLETED PHASE3
Bictegravir in the Elderly Living With HIV (BICEP)
NCT05064020 ACTIVE_NOT_RECRUITING
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
NCT00612898 TERMINATED PHASE2/PHASE3
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
NCT00450580 COMPLETED PHASE3
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
NCT00004580 COMPLETED PHASE1
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
NCT00224445 COMPLETED PHASE4
ATV/Ritonavir Nevirapine Interaction (USPAC)
NCT00162149 COMPLETED PHASE1
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
NCT02238314 COMPLETED PHASE2
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.
NCT01237444 COMPLETED PHASE3
Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects
NCT02251223 COMPLETED PHASE1/PHASE2